Martin Driscoll

CEO & Chair, RIGImmune, Inc.

Mr. Driscoll has more than 40 years of experience in the biopharmaceutical industry. Including his current role at RIGImmune, Marty has served as the chief executive officer of six biopharmaceutical development companies, including two publicly traded firms. Prior to joining RIGImmune, Marty was the chief executive officer of OncoNano. Marty led the successful merger of Spring Bank (SBPH: NASDAQ) with F-star Therapeutics (NASDAQ: FSTX) in November 2020. Marty’s career in the industry has included deep experience in biopharmaceutical product development, commercialization, financing for both private and public companies, M&A, and business development transactions. Mr. Driscoll has served as a director on the boards of eight public and private companies. Marty is the chair of the board of directors for RIGImmune, Inc. Mr. Driscoll received a B.Sc. in Communications from the University of Texas at Austin.

Back to About Us